Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01585350 · ClinicalTrials.gov registry record · Phase 1
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients
A Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT01585350 is a Phase 1 study that has completed, run by Craig L Slingluff, Jr. The registered enrollment target is 53 participants.
The verdict
NCT01585350, a Phase 1 study, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to learn the effects an experimental vaccine (MELITAC 12.1) combined with other substances called lipopolysaccharide (LPS; endotoxin), polyICLC, and Montanide ISA-51. The LPS, polyICLC, and Montanide ISA-51 are included with the vaccine to test whether they have an effect on the MELITAC 12.1 vaccine. The study will also look at whether the experimental vaccine and these drugs cause any changes to the immune system.
Interventions
- BIOLOGICAL MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)
- BIOLOGICAL MELITAC 12.1 + Montanide ISA-51 + polyICLC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01585350
The ClinicalTrials.gov registry entry for NCT01585350 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS) is the first listed.
NCT01585350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01585350 about?
NCT01585350 is a clinical study titled "A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients". The purpose of this study is to learn the effects an experimental vaccine (MELITAC 12.1) combined with other substances called lipopolysaccharide (LPS; endotoxin), polyICLC, and Montanide ISA-51. The LPS, polyICLC, and Montanide ISA-51 are included with the vaccine to test whether they have an effec...
What is the current status of trial NCT01585350?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2012-10. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01585350?
The interventions under investigation include: MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS) (BIOLOGICAL), MELITAC 12.1 + Montanide ISA-51 + polyICLC (BIOLOGICAL).
Who is sponsoring clinical trial NCT01585350?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.